We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+49.94%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
(+33%)
Cap. Flow
-$3.86M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.2M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$14.5M |
| 3 |
Cytokinetics
CYTK
|
+$13.8M |
| 4 |
Dyne Therapeutics
DYN
|
+$13.8M |
| 5 |
Zai Lab
ZLAB
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HilleVax
HLVX
|
+$21.1M |
| 2 |
CG Oncology
CGON
|
+$20M |
| 3 |
Disc Medicine
IRON
|
+$12.9M |
| 4 |
Cogent Biosciences
COGT
|
+$12.5M |
| 5 |
Travere Therapeutics
TVTX
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Valneva
VALN
$554M
| $28M | 0.84% |
2,291,666
+833,333
| +57% | +$7.12M |
2025 Q2
1 quarter
|
|
|
RNAM
27
DELISTED
Avidity Biosciences
RNAM
| $27.2M | 0.82% |
625,000
| – | – |
2025 Q1
2 quarters
|
|
28
Ascendis Pharma A/S
ASND
$15.2B
| $26.5M | 0.79% |
133,333
| – | – |
2024 Q3
4 quarters
|
|
29
Alkermes
ALKS
$6.74B
| $21M | 0.63% |
700,647
-300,000
| -30% | -$8.46M |
2024 Q3
4 quarters
|
|
30
Mereo BioPharma
MREO
$50.3M
| $19.4M | 0.58% |
9,440,112
| – | – |
2024 Q2
5 quarters
|
|
31
DELISTED
Akero Therapeutics
AKRO
| $17.4M | 0.52% |
366,784
| – | – |
2025 Q2
1 quarter
|
|
32
Vaxcyte
PCVX
$10.5B
| $17.1M | 0.51% |
474,405
| – | – |
2022 Q1
14 quarters
|
|
33
Evolus
EOLS
$497M
| $16.2M | 0.48% |
2,630,665
+195,115
| +8% | +$1.52M |
2025 Q2
1 quarter
|
|
34
Design Therapeutics
DSGN
$618M
| $14.7M | 0.44% |
1,953,547
| – | – |
2024 Q2
5 quarters
|
|
35
Immunocore
IMCR
$1.51B
| $14M | 0.42% |
384,782
| – | – |
2024 Q2
5 quarters
|
|
|
36
Acadia Pharmaceuticals
ACAD
$3.4B
| $13.1M | 0.39% |
+613,837
| New | +$14.5M |
2025 Q3
0 quarters
|
|
37
Jade Biosciences
JBIO
$880M
| $12.2M | 0.37% |
1,413,280
-358,836
| -20% | -$2.93M |
2025 Q2
1 quarter
|
|
38
Assembly Biosciences
ASMB
$416M
| $11.7M | 0.35% |
+456,249
| New | +$10M |
2025 Q3
0 quarters
|
|
39
DELISTED
Adverum Biotechnologies
ADVM
| $9.41M | 0.28% |
2,077,431
+1,008,187
| +94% | +$2.97M |
2024 Q1
6 quarters
|
|
|
40
Travere Therapeutics
TVTX
$5.14B
| $9.37M | 0.28% |
392,092
-610,000
| -61% | -$11.5M |
2025 Q2
1 quarter
|
|
41
NewAmsterdam Pharma Warrant
NAMSW
| $8.56M | 0.26% |
500,333
| – | – |
2022 Q4
11 quarters
|
|
42
enGene Therapeutics
ENGN
$107M
| $7.9M | 0.24% |
+1,157,380
| New | +$5.28M |
2025 Q3
0 quarters
|
|
43
Autolus Therapeutics
AUTL
$452M
| $7.54M | 0.23% |
4,623,324
| – | – |
2022 Q1
14 quarters
|
|
44
MacroGenics
MGNX
$212M
| $5.34M | 0.16% |
3,175,665
| – | – |
2023 Q1
10 quarters
|
|
45
Silence Therapeutics
SLN
$556M
| $5.03M | 0.15% |
970,130
| – | – |
2022 Q1
14 quarters
|
|
46
Allogene Therapeutics
ALLO
$466M
| $4.8M | 0.14% |
3,868,750
| – | – |
2024 Q1
6 quarters
|
|
47
Crescent Biopharma
CBIO
$479M
| $3.25M | 0.1% |
272,951
-180,734
| -40% | -$2.4M |
2025 Q2
1 quarter
|
|
|
48
CG Oncology
CGON
$5.47B
| – | – |
-770,000
| Closed | -$20M | – |
|
|
49
Cogent Biosciences
COGT
$5.02B
| – | – |
-1,734,601
| Closed | -$12.5M | – |
|
50
DELISTED
Elevation Oncology
ELEV
| – | – |
-5,993,579
| Closed | -$2.2M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2025 Portfolio in Review
As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
- Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
- Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
- Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
- Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
- Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
- Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.